Literature DB >> 29173186

Comparison of Physicochemical Properties of Generic Doxorubicin HCl Liposome Injection with the Reference Listed Drug.

Kuntal Maiti1, Subhas Bhowmick2, Pankaj Jain1, Murlidhar Zope1, Keyur Doshi1, Thennati Rajamannar2.   

Abstract

BACKGROUND: Liposomal doxorubicin is widely used for treating ovarian cancer and Kaposi's sarcoma. Encapsulation of doxorubicin in highly complex polyethylene glycol-coated (stealth) liposomes prolongs residence time and avoids the systemic toxicity associated with administration of the free drug. Small variations in physicochemical properties introduced during manufacture of liposomes can influence the payload of encapsulated drug, stability of liposomes under physiological conditions, and release of drug at the target tissue. Accordingly, the US Food and Drug Administration and the European Medicines Agency have issued guidance for manufacturers of generic liposomal doxorubicin that is designed to ensure that more than 30 physicochemical parameters that influence its safety and efficacy should be similar in the generic and reference listed drugs.
OBJECTIVE: This study aims to describe the physicochemical characterization procedures used to ensure consistency between batches of generic liposomal doxorubicin and with the reference listed drug.
METHODS: A range of spectroscopic, chromatographic, and other physicochemical tests was used to compare relative concentrations of liposome components, liposome morphology, ratios of free/entrapped doxorubicin, stability, and in vitro doxorubicin release rates in physiologically and clinically relevant media.
RESULTS: The tests established that generic and reference liposomes contained similar concentrations of drug, lipids, and excipients and that their physical forms were also similar.
CONCLUSION: The results of the tests demonstrate the physicochemical equivalence of generic liposomal doxorubicin hydrochloride and the reference listed drug, Doxil®/Caelyx®. Biochemical and clinical equivalence must also be demonstrated to fully meet regulatory requirements for generic liposomal medicines, and these are the subjects of separate studies. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Doxorubicin hydrochloride; cancer; generic; liposome; physicochemical equivalence; sterically stable.

Mesh:

Substances:

Year:  2018        PMID: 29173186     DOI: 10.2174/1871520617666171121124610

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  3 in total

1.  Analysis and evaluation of DRCOP scheme based on polyethylene glycol liposome doxorubicin in patients with diffuse large B-cell lymphoma.

Authors:  Chunyan Liu; Minjuan Zhang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  Effect of Paclitaxel Combined with Doxorubicin Hydrochloride Liposome Injection in the Treatment of Osteosarcoma and MRI Changes before and after Treatment.

Authors:  Ning Tian; Dongmei Wang; Xiaobao Li; Minghua Xue; Bo Zheng
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-30       Impact factor: 2.650

Review 3.  Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs.

Authors:  Rodrigo Dos A Miguel; Amanda S Hirata; Paula C Jimenez; Luciana B Lopes; Leticia V Costa-Lotufo
Journal:  Pharmaceutics       Date:  2022-08-17       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.